Emerging roles of FOXK2 in cancers and metabolic disorders

Xiaoke Xing; Xiangyong Que; Sihao Zheng; Shuxian Wang; Qibin Song; Yi Yao; Pingfeng Zhang

doi:10.3389/fonc.2024.1376496

Emerging roles of FOXK2 in cancers and metabolic disorders

Front Oncol. 2024 Apr 29:14:1376496. doi: 10.3389/fonc.2024.1376496. eCollection 2024.

Authors

Xiaoke Xing¹, Xiangyong Que¹, Sihao Zheng¹, Shuxian Wang¹, Qibin Song¹, Yi Yao¹, Pingfeng Zhang¹

Affiliation

¹ Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

Abstract

FOXK2, a member of the Forkhead box K (FOXK) transcription factor family, is widely expressed in various tissues and organs throughout the body. FOXK2 plays crucial roles in cell proliferation, differentiation, autophagy, de novo nucleotide biosynthesis, DNA damage response, and aerobic glycolysis. Although FOXK2 is recognized as an oncogene in colorectal cancer and hepatocellular carcinoma, it acts as a tumor suppressor in breast cancer, cervical cancer, and non-small cell lung cancer (NSCLC). This review provides an overview of the recent progress in understanding the regulatory mechanisms of FOXK2 and its downstream targets, highlights the significant impact of FOXK2 dysregulation on cancer etiology, and discusses the potential of targeting FOXK2 for cancer treatment.

Keywords: FOXK2; cancer; chemotherapy resistance; de novo nucleotide synthesis; metabolic disorders; post-translational modifications.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Natural Science Foundation of Hubei Province of China (2022CFB114).